MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Nicotine in Treating "Hunger Pain" in Patients With Malignant Bowel Obstruction Caused By Cancer

Not Applicable

Withdrawn

Conditions: Anorexia
Unspecified Adult Solid Tumor, Protocol Specific
Pain
Constipation, Impaction, and Bowel Obstruction
Psychosocial Effects of Cancer and Its Treatment

Interventions: Other: Placebo
Drug: nicotine
Procedure: Quality of life

First Posted Date: 2007-01-23

Last Posted Date: 2016-01-12

Lead Sponsor: Mayo Clinic

Registration Number: NCT00425906

Rituximab in Membranous Nephropathy

Phase 2

Completed

Conditions: Membranous Nephropathy

First Posted Date: 2007-01-22

Last Posted Date: 2011-02-25

Lead Sponsor: Mayo Clinic

Target Recruit Count: 15

Registration Number: NCT00425217

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Local Anesthesia for Prostate Biopsy

Phase 4

Completed

Conditions: Prostate Cancer

First Posted Date: 2007-01-17

Last Posted Date: 2010-01-20

Lead Sponsor: Mayo Clinic

Target Recruit Count: 243

Registration Number: NCT00422708

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Open-Label Adalimumab for Ulcerative Colitis Patients

Phase 1

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2007-01-12

Last Posted Date: 2012-08-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT00421642

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Using Networks, Informatics, Technology, and Education in Care for People With Diabetes

Not Applicable

Completed

Conditions: Diabetes Mellitus

First Posted Date: 2007-01-12

Last Posted Date: 2011-05-23

Lead Sponsor: Mayo Clinic

Target Recruit Count: 3491

Registration Number: NCT00421850

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Anemia
Lymphoproliferative Disorder
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: darbepoetin alfa
Drug: epoetin alfa
Procedure: fatigue assessment and management
Procedure: quality-of-life assessment

First Posted Date: 2006-12-28

Last Posted Date: 2017-02-10

Lead Sponsor: Mayo Clinic

Target Recruit Count: 239

Registration Number: NCT00416624

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Bupropion SR for Treating Smokeless Tobacco Use

Phase 3

Completed

Conditions: Smokeless Tobacco

First Posted Date: 2006-12-21

Last Posted Date: 2011-03-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 225

Registration Number: NCT00414180

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Study of Pyridostigmine in Postural Tachycardia Syndrome

Phase 2

Recruiting

Conditions: Postural Tachycardia Syndrome

Interventions: Drug: pyridostigmine
Drug: Placebo

First Posted Date: 2006-12-08

Last Posted Date: 2024-03-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT00409435

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Primary Peritoneal Cavity Cancer
Ovarian Cancer

Interventions: Biological: carcinoembryonic antigen-expressing measles virus
Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter
Genetic: reverse transcriptase-polymerase chain reaction
Other: laboratory biomarker analysis

First Posted Date: 2006-12-07

Last Posted Date: 2024-01-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 37

Registration Number: NCT00408590

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: gemcitabine HCL
Drug: pemetrexed disodium

First Posted Date: 2006-12-05

Last Posted Date: 2019-05-02

Lead Sponsor: Mayo Clinic

Target Recruit Count: 19

Registration Number: NCT00407550

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy